A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
Anxiety Disorder
About this trial
This is an interventional treatment trial for Anxiety Disorder focused on measuring Anxiety, Generalized Anxiety Disorder
Eligibility Criteria
Inclusion Criteria: Complete Study 04-001-01 Able to take the medication for 9 months Understand and sign the Informed Consent Comply with all study-related procedures Women of child bearing potential must have a confirmed negative urine pregnancy test Lack of clinically significant abnormalities in health Exclusion Criteria: Experienced any SAEs (serious adverse events) that were related or possibly related to study drug during participation in Study 04-001-01 Early termination from study 04-001-01 Any new condition that could interfere with the evaluation of the subject, interpretation of safety data, or compliance with the protocol requirements Experiencing AEs (adverse events) such that in the opinion of the investigator, per protocol, study drug administration or safe participation in this study would be precluded. Taken any disallowed medications noted in Study 04-001-01 between the completion of Study 04-001-01 and entry into this trial
Sites / Locations
- Florida Clinical Research Center
- Clinical Neuroscience Solutions, Inc.
- Meridien Research
- CNS Research Institute (CRI)
- Midwest Clinical Research Center
- Neurology and NeuroscienceCenter of Ohio
- IPS Research Company
- Oregon Center for Clinical Research, Inc.
- Suburban Research Associates
- CNS Research Institute (CRI)
- Future Search Trials
- Comprehensive Neuroscience of Northern Virginia
- Northwest Clinical Research Center